Published in Blood on October 01, 2002
Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors. Cancer Res (2007) 1.49
Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity. FASEB J (2008) 1.19
Inducible nitric oxide synthase in T cells regulates T cell death and immune memory. J Clin Invest (2004) 1.15
Immune regulatory effect of pHSP65 DNA therapy in pulmonary tuberculosis: activation of CD8+ cells, interferon-gamma recovery and reduction of lung injury. Immunology (2004) 1.09
MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model. Vaccine (2006) 1.07
TLR9 engagement on CD4 T lymphocytes represses gamma-radiation-induced apoptosis through activation of checkpoint kinase response elements. Blood (2007) 1.01
Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles. Nucleic Acids Res (2003) 0.98
Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse. Blood (2007) 0.96
Effects of Toll-like receptor signals in T-cell neoplasms. Future Oncol (2011) 0.79
Antigen-free adjuvant assists late effector CD4 T cells to transit to memory in lymphopenic hosts. J Immunol (2013) 0.76
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42
HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med (2010) 4.00
Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest (2010) 3.97
Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med (2010) 2.21
Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol (2010) 2.20
Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol Rev (2008) 2.07
Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. J Clin Invest (2011) 2.01
Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol (2004) 1.71
Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors. Cancer Res (2007) 1.49
Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects. Cancer Res (2009) 1.49
Chronic caloric restriction preserves mitochondrial function in senescence without increasing mitochondrial biogenesis. Cell Metab (2012) 1.44
PKCtheta is required for alloreactivity and GVHD but not for immune responses toward leukemia and infection in mice. J Clin Invest (2009) 1.37
Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res (2003) 1.32
Interferon γ limits the effectiveness of melanoma peptide vaccines. Blood (2010) 1.26
Inhibition of EBV-induced lymphoproliferation by CD4(+) T cells specific for an MHC class II promiscuous epitope. J Immunol (2002) 1.21
Proteomic identification of non-Gal antibody targets after pig-to-primate cardiac xenotransplantation. Xenotransplantation (2008) 1.17
ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis. J Clin Invest (2014) 1.16
Immune-mediated tumor regression induced by CpG-containing oligodeoxynucleotides. Clin Cancer Res (2003) 1.16
Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses. J Immunol (2004) 1.15
Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen. Cancer Res (2002) 1.15
In vivo expansion, persistence, and function of peptide vaccine-induced CD8 T cells occur independently of CD4 T cells. Cancer Res (2008) 1.14
A potent vaccination strategy that circumvents lymphodepletion for effective antitumor adoptive T-cell therapy. Cancer Res (2012) 1.14
PRDM1/Blimp-1 controls effector cytokine production in human NK cells. J Immunol (2010) 1.11
Lung tumor NF-κB signaling promotes T cell-mediated immune surveillance. J Clin Invest (2013) 1.08
Retracted B7-DC cross-linking restores antigen uptake and augments antigen-presenting cell function by matured dendritic cells. Proc Natl Acad Sci U S A (2005) 1.07
Blockade of LIGHT/LTbeta and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease. J Clin Invest (2002) 1.07
Challenges in the development of effective peptide vaccines for cancer. Mayo Clin Proc (2002) 1.05
Peptide epitope identification for tumor-reactive CD4 T cells. Curr Opin Immunol (2008) 1.03
CCR5 mediates Fas- and caspase-8 dependent apoptosis of both uninfected and HIV infected primary human CD4 T cells. AIDS (2002) 1.03
Direct costimulation of tumor-reactive CTL by helper T cells potentiate their proliferation, survival, and effector function. Clin Cancer Res (2002) 1.02
Optimized DNA vaccines to specifically induce therapeutic CD8 T cell responses against autochthonous breast tumors. Cancer Immunol Immunother (2008) 1.02
Relative quantification: characterization of bias, variability and fold changes in mass spectrometry data from iTRAQ-labeled peptides. J Proteome Res (2011) 1.02
BiVax: a peptide/poly-IC subunit vaccine that mimics an acute infection elicits vast and effective anti-tumor CD8 T-cell responses. Cancer Immunol Immunother (2012) 1.02
TriVax-HPV: an improved peptide-based therapeutic vaccination strategy against human papillomavirus-induced cancers. Cancer Immunol Immunother (2012) 1.01
Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen. Clin Cancer Res (2002) 1.01
T helper lymphocytes rescue CTL from activation-induced cell death. J Immunol (2006) 1.00
Interleukin 15 promotes antigen-independent in vitro expansion and long-term survival of antitumor cytotoxic T lymphocytes. Clin Cancer Res (2002) 1.00
Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence of systemic immune dysfunction. Cancer (2007) 1.00
Vaccine-elicited CD8+ T cells protect against respiratory syncytial virus strain A2-line19F-induced pathogenesis in BALB/c mice. J Virol (2012) 0.98
Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization. Am J Clin Oncol (2006) 0.97
Adoptive transfer of Tc1 or Tc17 cells elicits antitumor immunity against established melanoma through distinct mechanisms. J Immunol (2013) 0.96
Elevated levels of phosphorylated fibrinogen-alpha-isoforms and differential expression of other post-translationally modified proteins in the plasma of ovarian cancer patients. J Proteome Res (2006) 0.93
Autophagy induced by conventional chemotherapy mediates tumor cell sensitivity to immunotherapy. Cancer Res (2012) 0.90
Combinatorial immunotherapy of polyinosinic-polycytidylic acid and blockade of programmed death-ligand 1 induce effective CD8 T-cell responses against established tumors. Clin Cancer Res (2014) 0.90
Identification of naturally processed helper T-cell epitopes from prostate-specific membrane antigen using peptide-based in vitro stimulation. Clin Cancer Res (2003) 0.89
Oxidized lipids block antigen cross-presentation by dendritic cells in cancer. J Immunol (2014) 0.89
Induction of MAGE-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma. Head Neck (2012) 0.88
Enhancing immunogenicity of a CTL epitope from carcinoembryonic antigen by selective amino acid replacements. Clin Cancer Res (2002) 0.87
Recognition of six-transmembrane epithelial antigen of the prostate-expressing tumor cells by peptide antigen-induced cytotoxic T lymphocytes. Clin Cancer Res (2005) 0.87
Transcutaneous immunization with cytotoxic T-cell peptide epitopes provides effective antitumor immunity in mice. J Immunother (2005) 0.86
Recognition of prostate and melanoma tumor cells by six-transmembrane epithelial antigen of prostate-specific helper T lymphocytes in a human leukocyte antigen class II-restricted manner. Cancer Res (2007) 0.86
Defining MHC class II T helper epitopes for WT1 tumor antigen. Cancer Immunol Immunother (2005) 0.86
T-cell epitope peptide vaccines. Expert Rev Vaccines (2004) 0.85
STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice. Cancer Immunol Immunother (2015) 0.84
Recognition of prostate and breast tumor cells by helper T lymphocytes specific for a prostate and breast tumor-associated antigen, TARP. Clin Cancer Res (2005) 0.84
Optimized combination therapy using bortezomib, TRAIL and TLR agonists in established breast tumors. Cancer Immunol Immunother (2010) 0.84
Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells. Cancer Res (2008) 0.84
Six-transmembrane epithelial antigen of the prostate and enhancer of zeste homolog 2 as immunotherapeutic targets for lung cancer. J Transl Med (2011) 0.84
Immunogenicity of protein therapeutics and the interplay between tolerance and antibody responses. Drug Discov Today (2007) 0.83
Direct cross-priming by th lymphocytes generates memory cytotoxic T cell responses. J Immunol (2005) 0.83
Antigen-independent acquisition of MHC class II molecules by human T lymphocytes. Int Immunol (2004) 0.83
Intratumoral electroporation of IL-12 cDNA eradicates established melanomas by Trp2(180-188)-specific CD8+ CTLs in a perforin/granzyme-mediated and IFN-γ-dependent manner: application of Trp2(180-188) peptides. Cancer Immunol Immunother (2012) 0.83
Design of immunogenic and effective multi-epitope DNA vaccines for melanoma. Cancer Immunol Immunother (2011) 0.82
Novel toll-like receptor 2 ligands for targeted pancreatic cancer imaging and immunotherapy. J Med Chem (2012) 0.81
Lack of effective T-lymphocyte response to the PAX3/FKHR translocation area in alveolar rhabdomyosarcoma. Cancer Immunol Immunother (2004) 0.81
Inflammation and the depot-specific secretome of human preadipocytes. Obesity (Silver Spring) (2015) 0.81
Recognition of adult T-cell leukemia/lymphoma cells by CD4+ helper T lymphocytes specific for human T-cell leukemia virus type I envelope protein. Clin Cancer Res (2004) 0.81
CCL17 and CCL22/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer/T-cell lymphoma. Cancer Immunol Immunother (2015) 0.81
Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen. Cancer Res (2007) 0.81
Induction of tumor-reactive T helper responses by a posttranslational modified epitope from tumor protein p53. Cancer Immunol Immunother (2014) 0.80
Stimulatory effects of CpG oligodeoxynucleotide on dendritic cell-based immunotherapy of colon cancer in CEA/HLA-A2 transgenic mice. Int J Cancer (2009) 0.80
Tumor-derived TGF-β and prostaglandin E2 attenuate anti-tumor immune responses in head and neck squamous cell carcinoma treated with EGFR inhibitor. J Transl Med (2014) 0.80
Identification and characterization of a T-helper peptide from carcinoembryonic antigen. Clin Cancer Res (2004) 0.80
Oral administration of PPC enhances antigen-specific CD8+ T cell responses while reducing IgE levels in sensitized mice. BMC Complement Altern Med (2009) 0.79
A naturally processed HLA-DR-bound peptide from the IL-9 receptor alpha of HTLV-1-transformed T cells serves as a T helper epitope. Cancer Immunol Immunother (2012) 0.79
Avoiding Tolerance Against Prostatic Antigens With Subdominant Peptide Epitopes. J Immunother (1991) (2001) 0.78
Overcoming doubts and other obstacles in the development of effective peptide-based therapeutic vaccines against cancer. Expert Rev Vaccines (2010) 0.78
In vitro peptide immunization of target tax protein human T-cell leukemia virus type 1-specific CD4+ helper T lymphocytes. Clin Cancer Res (2006) 0.78
Unpasteurized milk consumption and subsequent risk of cancer. Cancer Causes Control (2008) 0.78
Functional analysis of birch pollen allergen Bet v 1-specific regulatory T cells. J Immunol (2007) 0.78
In vitro induction of immune responses to shared tumor-associated antigens in rhabdomyosarcoma. J Pediatr Surg (2007) 0.78
Generation of tumoricidal PAX3 peptide antigen specific cytotoxic T lymphocytes. Int J Cancer (2006) 0.77
Characterization of human CD4 helper T cell responses against Aurora kinase A. Cancer Immunol Immunother (2010) 0.76
NF-κB is crucial in proximal T-cell signaling for calcium influx and NFAT activation. Eur J Immunol (2014) 0.76
Focal adhesion kinase as an immunotherapeutic target. Cancer Immunol Immunother (2008) 0.75
Combination cytokine therapy inhibits tumor growth by generation of tumor-specific T-cell responses in a murine melanoma model. Cytokine (2010) 0.75
Retraction for Radhakrishnan et al., B7-DC cross-linking restores antigen uptake and augments antigen-presenting cell function by matured dendritic cells. Proc Natl Acad Sci U S A (2010) 0.75